Author： Nurmohamed Michael T.
Publisher： Adis International
ISSN： 0012-6667
Source： Drugs, Vol.69, Iss.15, 2009-10, pp. : 2035-2043
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Access to resources
Recommend
Ipilimumab: will benefits outweigh risks in the eyes of the FDA?
Reactions Weekly, Vol. 1, Iss. 1307, 2010-01 ,pp. :
Aluminium in Over-the-Counter Drugs: Risks Outweigh Benefits?
By Reinke C.M.
Drug Safety, Vol. 26, Iss. 14, 2003-01 ,pp. :
Newer drugs for rheumatoid arthritis worth their cost?
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 338, 2001-01 ,pp. :
Is There a Role for Antibiotics in the Treatment of Patients with Rheumatoid Arthritis?
By ODell J.R.
Drugs, Vol. 57, Iss. 3, 1999-03 ,pp. :